On a per-share basis, the
The results exceeded
The biopharmaceutical company posted revenue of
For the year, the company reported that its loss narrowed to
Intra-Cellular shares have dropped 39% since the beginning of the year. The stock has increased 52% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a
Automated Insights, source